Iovance Biotherapeutics inc (IOVA) - News Archive

SAN CARLOS, Calif. On September 19, 2025, Iovance Biotherapeutics, Inc., a leading biotechnology firm distinguished for its pioneering work in polyclonal tumor infiltrating lymphocyte (TIL) therapies, announced a signif...

In the volatile world of pharmaceutical stocks, recent developments surrounding Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) have sent ripples of concern through the investment community. The esteemed Rosen Law Firm, a...

A Balanced Perspective on the Legal Proceedings Facing Iovance Biotherapeutics and Its Market Position for CSIMarket.com Context and Legal Developments Iovance Biotherapeutics, Inc. a biotechnology company focused on th...

In-depth Analysis: Navigating Strategic Growth and Market Realities in BiotechIovance Biotherapeutics, Inc. (NASDAQ: IOVA), a prominent player in the field of biotechnology, continues to forge ahead with its bold commit...

In an effort to bolster innovation and maintain a competitive edge within the biotechnology sector, Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) has announced a series of inducement stock grants aimed at attracting and...

On January 17, 2025, Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a company dedicated to the advancement of innovative treatments for cancer, announced a significant step in its growth strategy. In a press release, Iov...

for : Iovance Biotherapeutics Leverages Inducement Grants to Attract Talent Amid Tumultuous Biotech LandscapeIn the competitive sphere of biotechnology, the strategic maneuvering of talent acquisition is pivotal to inno...

Iovance Biotherapeutics, a leading biotechnology company specializing in innovative cancer therapies, recently announced the approval of new stock options and restricted stock units for twenty-four non-executive employe...

Iovance Biotherapeutics, a biotechnology company dedicated to developing innovative polyclonal tumor infiltrating lymphocyte (TIL) therapies for cancer patients, recently announced the approval of inducement stock optio...

In recent announcements, Iovance Biotherapeutics, a leading biotechnology company focused on developing innovative polyclonal tumor infiltrating lymphocyte (TIL) therapies for cancer patients, has disclosed significant...

Iovance Biotherapeutics Announces Clinical Data in Frontline Advanced Melanoma at ASCO 2024 Annual MeetingLifileucel TIL Cell Therapy in Combination with Pembrolizumab Demonstrates Deep, Durable Responses in Frontline A...

San Carlos, California In a bid to strengthen its workforce and advance groundbreaking cancer therapies, Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) announced the approval of inducement stock options on May 16, 2024. T...

The emerging field of immuno-oncology has witnessed significant advancements in recent years, with Lifileucel and Pembrolizumab demonstrating promising results in the treatment of advanced frontline melanoma. The of thi...

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)SAN CARLOS, Calif., April 19, 2024 - Iovance Biotherapeutics, a biotechnology company specializing in innovative tumor infiltrating l...

SAN CARLOS, Calif. - In a strategic move towards attracting and retaining top talent, biotechnology company Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) recently announced the approval of inducement stock options for tw...

In a recent press release, Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a leading biotechnology company, announced the pricing of an underwritten offering of its common stock. This offering is expected to generate appr...

Iovance Biotherapeutics Continues to Expand Team and Enhance Shareholder Value Through Inducement Stock Options GrantsSAN CARLOS, Calif., Feb. 16, 2024 - Iovance Biotherapeutics, a biotechnology company specializing in...

Iovance s AMTAGVI (lifileucel) Receives U.S. FDA Accelerated Approval for Advanced MelanomaIn a groundbreaking development, the U.S. Food and Drug Administration (FDA) has granted accelerated approval to Iovance Biother...

The arena of cancer research and treatment is continually evolving with the tireless efforts and innovation of biotechnology firms globally. One such entity leading the charge is Iovance Biotherapeutics, Inc. (NASDAQ: I...

In a recent press release, Iovance Biotherapeutics, a leading biotechnology company dedicated to developing groundbreaking polyclonal tumor infiltrating lymphocyte (TIL) therapies for cancer patients, has announced the...